Solko W. Schalm

24.5k total citations · 2 hit papers
288 papers, 15.3k citations indexed

About

Solko W. Schalm is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Solko W. Schalm has authored 288 papers receiving a total of 15.3k indexed citations (citations by other indexed papers that have themselves been cited), including 248 papers in Hepatology, 233 papers in Epidemiology and 26 papers in Infectious Diseases. Recurrent topics in Solko W. Schalm's work include Hepatitis C virus research (180 papers), Hepatitis B Virus Studies (162 papers) and Liver Disease Diagnosis and Treatment (159 papers). Solko W. Schalm is often cited by papers focused on Hepatitis C virus research (180 papers), Hepatitis B Virus Studies (162 papers) and Liver Disease Diagnosis and Treatment (159 papers). Solko W. Schalm collaborates with scholars based in Netherlands, Germany and United States. Solko W. Schalm's co-authors include Robert A. de Man, Harry L.A. Janssen, Bettina E. Hansen, Hubert G.M. Niesters, Wim C.J. Hop, John G. O’Grady, R. B. Williams, Pieter Honkoop, Juan C. Quero and Stefan Zeuzem and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Annals of Internal Medicine.

In The Last Decade

Solko W. Schalm

285 papers receiving 14.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

2005 866 citations Harry L.A. Janssen, Guido Gerken et al. profile →
Acute liver failure: redefining the syndromes

1993 651 citations Solko W. Schalm et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Solko W. Schalm Netherlands	65	12.6k	12.1k	1.8k	1.3k	892	288	15.3k
P Opolon France	41	9.5k 0.8×	9.2k 0.8×	1.6k 0.9×	926 0.7×	425 0.5×	161	12.1k
Eugene R. Schiff United States	78	22.8k 1.8×	22.5k 1.9×	2.7k 1.5×	3.2k 2.4×	911 1.0×	372	28.9k
Karen L. Lindsay United States	52	9.5k 0.8×	9.0k 0.7×	643 0.4×	793 0.6×	420 0.5×	150	12.9k
Jorge Rakela United States	55	6.3k 0.5×	6.0k 0.5×	2.7k 1.5×	522 0.4×	518 0.6×	205	10.1k
Rafael Esteban Spain	57	14.0k 1.1×	12.6k 1.0×	1.4k 0.8×	2.1k 1.5×	244 0.3×	396	15.9k
Xavier Forns Spain	61	12.7k 1.0×	11.8k 1.0×	1.3k 0.7×	1.4k 1.0×	281 0.3×	325	15.0k
Richard K. Sterling United States	66	13.7k 1.1×	15.8k 1.3×	4.4k 2.5×	827 0.6×	496 0.6×	326	20.6k
Ira M. Jacobson United States	64	17.0k 1.3×	15.7k 1.3×	962 0.5×	3.0k 2.2×	274 0.3×	338	19.9k
Vinod K. Rustgi United States	35	11.9k 0.9×	10.7k 0.9×	690 0.4×	1.6k 1.2×	233 0.3×	173	13.8k
Jacob George Australia	52	6.4k 0.5×	11.6k 1.0×	1.9k 1.1×	700 0.5×	595 0.7×	275	15.4k

Countries citing papers authored by Solko W. Schalm

Since Specialization

Citations

This map shows the geographic impact of Solko W. Schalm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Solko W. Schalm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Solko W. Schalm more than expected).

Fields of papers citing papers by Solko W. Schalm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Solko W. Schalm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Solko W. Schalm. The network helps show where Solko W. Schalm may publish in the future.

Co-authorship network of co-authors of Solko W. Schalm

This figure shows the co-authorship network connecting the top 25 collaborators of Solko W. Schalm. A scholar is included among the top collaborators of Solko W. Schalm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Solko W. Schalm. Solko W. Schalm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Terrault, Norah A., Solko W. Schalm, George Papatheodoridis, et al.. (2007). [483] PRESENCE OF BIOPSY-PROVEN HISTOLOGIC DAMAGE (NECROINFLAMMATION AND FIBROSIS) IS COMMON EVEN WHEN ALT IS LESS THAN 2 × ULN IN PATIENTS WITH CHRONIC HEPATITIS B (CHB). Journal of Hepatology. 46. S184–S184. 7 indexed citations

Leusen, R. van, Rob P. Adang, R. A. de Vries, et al.. (2007). Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrology Dialysis Transplantation. 23(2). 721–725. 44 indexed citations

Tang, Thjon J., Robert A. de Man, Johannes G. Kusters, et al.. (2003). Intrahepatic CD8 T‐lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients. Journal of Medical Virology. 72(2). 215–222. 14 indexed citations

Vrolijk, Jan Maarten, Artur Kaul, Bettina E. Hansen, et al.. (2003). A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. Journal of Virological Methods. 110(2). 201–209. 151 indexed citations

Willems, M., et al.. (2002). Liver transplantation and hepatitis C. Transplant International. 15(2-3). 61–72. 33 indexed citations

Bekkering, Frank C., Johannes T. Brouwer, Bettina E. Hansen, & Solko W. Schalm. (2001). Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. Journal of Hepatology. 34(3). 435–440. 28 indexed citations

Heijtink, R. A., et al.. (1999). Characteristics of the early phase of chronicity in acute hepatitis B infection. Journal of Medical Virology. 57(4). 331–336. 12 indexed citations

Schalm, Solko W.. (1998). Adding ribavirin to interferon α-2b for chronic hepatitis C infection increased virological response and nausea. Gut. 43(5). 602–602. 1 indexed citations

Honkoop, Pieter, et al.. (1997). Lamivudine resistance inimmunocompetent chronic hepatitis B. Journal of Hepatology. 26(6). 1393–1395. 247 indexed citations

10.

Fattovich, Giovanna, G. Giustina, G. Realdi, & Solko W. Schalm. (1996). Effectiveness of interferon alfa on the clinical course of caucasian patients with viral compensated cirrhosis. Hepatology. 24. 155–155. 1 indexed citations

11.

Krogsgaard, Kim, Niels Bindslev, Erik Christensen, et al.. (1994). The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. Journal of Hepatology. 21(4). 646–655. 70 indexed citations

12.

Grosheide, P.M., et al.. (1994). Immunogenicity of two different dosages (10 and 5 μg) of recombinant DNA hepatitis B vaccine in healthy neonates. Vaccine. 12(14). 1323–1326. 5 indexed citations

13.

Janssen, Harry L.A., L Berk, Solko W. Schalm, et al.. (1992). Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B.. Gut. 33(8). 1094–1098. 22 indexed citations

14.

Berk, L, Solko W. Schalm, & R. A. Heijtink. (1991). Severe chronic active hepatitis (autoimmune type) mimicked by coinfection of hepatitis C and human immunodeficiency viruses.. Gut. 32(10). 1198–1200. 13 indexed citations

15.

Kramer, P., et al.. (1990). Hepatitis B vaccination of haemodialysis patients: randomized controlled trial comparing plasma‐derived vaccine with and without pre‐S2 antigen. European Journal of Clinical Investigation. 20(5). 540–545. 11 indexed citations

16.

Terpstra, Onno T., Solko W. Schalm, Willem Weimar, et al.. (1988). Auxiliary Partial Liver Transplantation for End-Stage Chronic Liver Disease. New England Journal of Medicine. 319(23). 1507–1511. 92 indexed citations

17.

Schalm, Solko W., et al.. (1984). Passive-active immunisation of neonates of HBsAg positive carrier mothers: preliminary observations.. BMJ. 288(6416). 513–515. 18 indexed citations

18.

Schalm, Solko W.. (1982). Treatment of chronic active hepatitis. Liver International. 2(2). 69–76. 9 indexed citations

19.

Uribe, Misael, Solko W. Schalm, W.H.J. Summerskill, & V. L. W. Go. (1978). Oral prednisone for chronic active liver disease: dose responses and bioavailability studies.. Gut. 19(12). 1131–1135. 49 indexed citations

20.

Schalm, Solko W., W.H.J. Summerskill, Gary Gitnick, & Lila R. Elveback. (1976). Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis BS antigen.. Gut. 17(10). 781–786. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact